SARS-CoV-2 active infection and antibodies amongst health personnel during the outbreak in Cameroon: Strengthening the health system for response to future public health emergencies.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2024
Historique:
received: 19 01 2024
accepted: 13 05 2024
medline: 31 5 2024
pubmed: 31 5 2024
entrez: 31 5 2024
Statut: epublish

Résumé

Health personnel (HP) are on the frontlines during response to public health emergencies like COVID-19. This risk of exposure suggests the need for safety in responding to any pandemic. Therefore, to ascertain the rate of SARS-CoV-2 infection and immunity, and their determinants amongst HP become relevant. A cross sectional health facility-based study was carried-out amongst HP in the Centre Region of Cameroon from 1st February to 30th June 2021. Characteristics and access to preventive tools were collected using face-to-face administered questionnaire. Nasopharyngeal swabs and whole blood were collected for PCR, IgG and IgM testing respectively. STATA version 17 software was used for data analysis. Determinants of COVID-19 infection were explored by estimating crude and adjusted Odd Ratio. Out of 510 HP reached, 458 were enrolled with mean age of 35 (±10) years. Thirty-four (7.4%) were PCR-positive to SARS-CoV-2 with 73.5% being clinicians versus 9 (26.4%) non-clinicians (p = 0.05). Sero-positivity to SARS-CoV-2 IgG/IgM was 40.2% (184/458), with 84.2% being clinicians versus 29 (15.8%) non-clinicians (p = 0.733). Amongst the 34 HP with PCR-positivity, 16 (47%) had no antibodies, while, 15 (44%) were IgG only. An estimate of HP (43.7%) had at least an evidence of PCR, IgG or IgM contact to COVID-19. Determinants of PCR-positivity was being clinical staff (AOR = 0.29, P = 0.039); and that of IgG/IgM were being non clinical staff (AOR = 0.41, p = 0.018) and regular use of face masks (AOR = 0.44, p = 0.001). HP trained on IPC (24%) were mainly from peripheral level (74.7%, p = 0.002). Active infections were within the range of pandemic control (<10%). However, around two-fifths of participants have had contact with the virus, indicating that HP remains a population at risk of COVID-19 and other similarly-transmitted epidemic prone diseases, and also an important source of transmission. There is need of vaccine to achieve protectiveness, and optimal response also requires capacity building to improve the health system when challenged by a future pandemic.

Sections du résumé

BACKGROUND BACKGROUND
Health personnel (HP) are on the frontlines during response to public health emergencies like COVID-19. This risk of exposure suggests the need for safety in responding to any pandemic. Therefore, to ascertain the rate of SARS-CoV-2 infection and immunity, and their determinants amongst HP become relevant.
METHODS METHODS
A cross sectional health facility-based study was carried-out amongst HP in the Centre Region of Cameroon from 1st February to 30th June 2021. Characteristics and access to preventive tools were collected using face-to-face administered questionnaire. Nasopharyngeal swabs and whole blood were collected for PCR, IgG and IgM testing respectively. STATA version 17 software was used for data analysis. Determinants of COVID-19 infection were explored by estimating crude and adjusted Odd Ratio.
RESULTS RESULTS
Out of 510 HP reached, 458 were enrolled with mean age of 35 (±10) years. Thirty-four (7.4%) were PCR-positive to SARS-CoV-2 with 73.5% being clinicians versus 9 (26.4%) non-clinicians (p = 0.05). Sero-positivity to SARS-CoV-2 IgG/IgM was 40.2% (184/458), with 84.2% being clinicians versus 29 (15.8%) non-clinicians (p = 0.733). Amongst the 34 HP with PCR-positivity, 16 (47%) had no antibodies, while, 15 (44%) were IgG only. An estimate of HP (43.7%) had at least an evidence of PCR, IgG or IgM contact to COVID-19. Determinants of PCR-positivity was being clinical staff (AOR = 0.29, P = 0.039); and that of IgG/IgM were being non clinical staff (AOR = 0.41, p = 0.018) and regular use of face masks (AOR = 0.44, p = 0.001). HP trained on IPC (24%) were mainly from peripheral level (74.7%, p = 0.002).
CONCLUSION CONCLUSIONS
Active infections were within the range of pandemic control (<10%). However, around two-fifths of participants have had contact with the virus, indicating that HP remains a population at risk of COVID-19 and other similarly-transmitted epidemic prone diseases, and also an important source of transmission. There is need of vaccine to achieve protectiveness, and optimal response also requires capacity building to improve the health system when challenged by a future pandemic.

Identifiants

pubmed: 38820301
doi: 10.1371/journal.pone.0304477
pii: PONE-D-23-44152
doi:

Substances chimiques

Antibodies, Viral 0
Immunoglobulin G 0
Immunoglobulin M 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0304477

Informations de copyright

Copyright: © 2024 Ngomtcho et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Clin Infect Dis. 2020 Nov 19;71(16):2027-2034
pubmed: 32221519
Epidemiol Infect. 2020 Sep 11;148:e208
pubmed: 32912370
J Hosp Infect. 2020 Aug;105(4):596-600
pubmed: 32565367
Ethics Med Public Health. 2021 Jun;17:100635
pubmed: 33553555
PLoS One. 2021 Apr 23;16(4):e0250699
pubmed: 33891659
PLoS One. 2020 May 19;15(5):e0233588
pubmed: 32428031
Int J Environ Res Public Health. 2022 Sep 30;19(19):
pubmed: 36231783
Pan Afr Med J. 2022 Mar 14;41:201
pubmed: 35685114
PLoS Med. 2022 Nov 10;19(11):e1004107
pubmed: 36355774
PLoS One. 2023 Jan 20;18(1):e0280269
pubmed: 36662746
J Hosp Infect. 2021 Feb;108:120-134
pubmed: 33212126
J Intern Med. 2022 Jan;291(1):32-50
pubmed: 34352148
Pan Afr Med J. 2020 Sep 23;37(Suppl 1):16
pubmed: 33343795
N Engl J Med. 2021 Jan 21;384(3):229-237
pubmed: 33113295
PLoS One. 2021 Sep 30;16(9):e0257845
pubmed: 34591920
BMJ. 2020 Sep 8;370:m3325
pubmed: 32900692
Pan Afr Med J. 2020 Oct 01;37(Suppl 1):19
pubmed: 33343798
Front Med. 2020 Apr;14(2):229-231
pubmed: 32212058
Immunol Med. 2021 Sep;44(3):187-196
pubmed: 33444511
Nat Commun. 2020 Aug 13;11(1):4049
pubmed: 32792562
Lancet Public Health. 2020 Sep;5(9):e475-e483
pubmed: 32745512
JAMA Netw Open. 2020 Mar 2;3(3):e203976
pubmed: 32202646
Front Med (Lausanne). 2022 Feb 04;8:758118
pubmed: 35186963
J Clin Virol. 2020 Jul;128:104437
pubmed: 32434708
Influenza Other Respir Viruses. 2024 Apr;18(4):e13267
pubmed: 38532666
Saf Health Work. 2020 Sep;11(3):262-265
pubmed: 32995051
Am J Trop Med Hyg. 2021 Jan;104(1):91-94
pubmed: 33185181
Int J Infect Dis. 2021 Apr;105:621-625
pubmed: 33711522
Front Public Health. 2021 Jun 25;9:606666
pubmed: 34249826
Int J Infect Dis. 2020 Nov;100:386-389
pubmed: 32949777

Auteurs

Sen Claudine Henriette Ngomtcho (SCH)

National Public Health Laboratory, Ministry of Public Health, Yaoundé, Cameroon.
Department of Microbiology, Hematology and Immunology, Faculty of Medicine and Pharmaceutical Sciences (FMPS), University of Dschang, Dschang, Cameroon.
Genomic Surveillance Study Group, Ministry of Public Health, Yaoundé, Cameroon.

Blaise Mboringong Akenji (BM)

National Public Health Laboratory, Ministry of Public Health, Yaoundé, Cameroon.

Ketina Hirma Tchio-Nighie (KH)

M.A. SANTE (Meilleur Accès aux Soins de Santé), Yaoundé, Cameroon.

Joseph Fokam (J)

Chantal Biya International Reference Centre for Research on HIV/AIDS Prevention and Management (CIRCB), Yaoundé, Cameroon.

Etienne Guenou (E)

National Public Health Laboratory, Ministry of Public Health, Yaoundé, Cameroon.

Carolle Nsa'Amang Eyebe (C)

Department of Biological Sciences, Faculty of Medicine and Pharmaceutical Sciences (FMPS), University of Douala, Douala, Cameroon.

Yvan Junior Nzegni Kamkoum (YJ)

Department of Microbiology, Hematology and Immunology, Faculty of Medicine and Pharmaceutical Sciences (FMPS), University of Dschang, Dschang, Cameroon.

Valdex Derick Ntale Tchoffo (VD)

Department of Microbiology, Hematology and Immunology, Faculty of Medicine and Pharmaceutical Sciences (FMPS), University of Dschang, Dschang, Cameroon.

Collins Buh Nkum (C)

M.A. SANTE (Meilleur Accès aux Soins de Santé), Yaoundé, Cameroon.

Hervé Christian Tchoudjin Paho (HC)

National Public Health Laboratory, Ministry of Public Health, Yaoundé, Cameroon.

Yvette Marie Solange Ebogo (YMS)

National Public Health Laboratory, Ministry of Public Health, Yaoundé, Cameroon.

Aude Nanfak (A)

M.A. SANTE (Meilleur Accès aux Soins de Santé), Yaoundé, Cameroon.

Martin Maidadi-Foudi (M)

Centre de Recherche en Maladies Emergentes et Re-emergentes (CREMER), Yaoundé, Cameroun.

Crescence Fouda (C)

National Public Health Laboratory, Ministry of Public Health, Yaoundé, Cameroon.

Angyiba Serge Andigema (AS)

Department of Microbiology, Hematology and Immunology, Faculty of Medicine and Pharmaceutical Sciences (FMPS), University of Dschang, Dschang, Cameroon.

Lilian Nsah Bongdze-Em (L)

Department of Microbiology, Hematology and Immunology, Faculty of Medicine and Pharmaceutical Sciences (FMPS), University of Dschang, Dschang, Cameroon.

Beri Nadin Nfor (BN)

Department of Microbiology, Hematology and Immunology, Faculty of Medicine and Pharmaceutical Sciences (FMPS), University of Dschang, Dschang, Cameroon.

Judith Torimiro (J)

Chantal Biya International Reference Centre for Research on HIV/AIDS Prevention and Management (CIRCB), Yaoundé, Cameroon.

Anne Cécile Zoung-Kanyi Bissek (AC)

Division for Operational Health Research (DROS), Ministry of Public Health, Yaoundé, Cameroon.
Department of internal Medicine, Faculty of Medicine and Biomedical Sciences, University of Yaoundé I, Yaoundé, Cameroon.

Michel Noubom (M)

Department of Microbiology, Hematology and Immunology, Faculty of Medicine and Pharmaceutical Sciences (FMPS), University of Dschang, Dschang, Cameroon.

Marie Claire Assoumou Okomo (MC)

National Public Health Laboratory, Ministry of Public Health, Yaoundé, Cameroon.

Jérôme Ateudjieu (J)

M.A. SANTE (Meilleur Accès aux Soins de Santé), Yaoundé, Cameroon.
Department of Public Health, Faculty of Medicine and Pharmaceutical Sciences, University of Dschang, Dschang, Cameroon.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH